# Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study

Study · id `cardio:ct-nct02642419` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02642419](<https://clinicaltrials.gov/study/NCT02642419>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02642419

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2200 participants.

## Technical summary

Registry record NCT02642419. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2200 participants (planned count; ClinicalTrials.gov record NCT02642419, source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02642419, source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)
- Primary completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02642419, source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)
- Completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02642419, source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02642419, source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02642419-2015-12-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
- Acronym: AFIRE
- Condition: Atrial Fibrillation
- Intervention (Drug): Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Japan Cardiovascular Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease (`cardio:pubmed-31475793`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis (`cardio:pubmed-33657403`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation (`cardio:pubmed-34261738`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial (`cardio:pubmed-35209924`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial (`cardio:pubmed-35704345`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease (`cardio:pubmed-37173099`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3acaa618119bdacbe4db13b95a2ce3d9d33a959ab4650ecb0478df61c31ecb70
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
